• Disease
  • Factor
  • Factor Viii
  • Erik Berntorp

    Prominent publications by Erik Berntorp

    KOL Index score: 15167

    BACKGROUND: A successful outcome of pregnancy requires an efficient uteroplacental vascular system. Since this system may be compromised by disorders of haemostasis associated with a prothrombotic state, we postulated that maternal thrombophilia might be a risk factor for fetal loss. We studied the relation between heritable thrombophilic defects and fetal loss in a cohort of women with factor V Leiden or deficiency of antithrombin, protein C, or protein S.

    METHODS: We studied 1384 women ...

    Also Ranks for: Fetal Loss |  women thrombophilia |  antithrombin deficiency |  stillbirth miscarriage |  combined defects
    KOL Index score: 13500

    INTRODUCTION: Having a child with a chronic disease often increases the burden in the family with more hospital visits, treatment administration, and increased worries for the ill child. A cross-sectional, international, multi-centre study in caregivers of children <18 years with haemophilia and inhibitor was performed at Haemophilia Treatment Centres in Sweden, UK, and Canada to evaluate caregivers' burden and their health-related quality of life (HRQoL) compared to that of caregivers ...

    Also Ranks for: Caregivers Children |  child haemophilia |  female followup studies |  factor inhibitors |  burden scale
    KOL Index score: 12298

    The development of antibodies to factor VIII is a serious complication of the treatment of patients with hemophilia A. We successfully induced immune tolerance in patients with such antibodies with a new treatment protocol, which combined factor VIII, cyclophosphamide, and high-dose intravenous IgG, followed by regular prophylactic treatment with factor VIII. This protocol has now been used in 11 patients with hemophilia A, of whom 9 had a strong antibody response. When the initial ...

    Also Ranks for: Factor Viii |  immune tolerance |  patients hemophilia |  intravenous igg |  combined treatment
    KOL Index score: 11442

    Patients with von Willebrand disease (VWD) and haemophilia A (HA) lack, to varying degrees, the von Willebrand factor (VWF) and coagulation factor VIII (FVIII) that are critical for normal haemostasis. These conditions in turn make patients prone to uncontrolled bleeding. Historically, patients with severe forms of VWD or HA were crippled before adulthood and their life expectancy was significantly reduced. Over the past decades, specific coagulation factor replacement therapies ...

    Also Ranks for: Vwf Fviii |  haemate patients |  willebrand factor |  gold standard |  uncontrolled bleeding
    KOL Index score: 11426

    This study prospectively evaluated the rate of biologic response to desmopressin (DDAVP) in 66 patients with type 1 or 2 von Willebrand disease (VWD), each of whom had, on the basis of available records, a clinically significant bleeding history and at least one of the following laboratory abnormalities: bleeding time (BT) longer than 15 minutes, ristocetin cofactor activity (VWF:RCo) less than 10 IU/dL, factor VIII coagulant activity (FVIII:C) less than 20 IU/dL (severe VWD). Before the ...

    Also Ranks for: Biologic Response |  type 2 |  ddavp patients |  1 vwd |  willebrand disease
    KOL Index score: 11405

    For many patients with von Willebrand disease (VWD), the replacement therapy with von Willebrand factor (VWF)/factor VIII (FVIII) concentrates is the treatment of choice. To evaluate clinical efficacy, safety and tolerability of Wilate, an albumin-free VWF/FVIII concentrate with a ratio of the two haemostatic moieties of approximately 1 to 1, a prospective clinical programme has been designed. The dataset on the treatment and prevention of bleedings is derived from 44 patients (20 males ...

    Also Ranks for: Willebrand Factor |  wilate treatment |  efficacy safety |  viii concentrate |  vwd types
    KOL Index score: 11188

    The primary aim of this study was to investigate the possible relationship between coagulation factor level and bleeding frequency during prophylactic treatment of haemophilia after stratification of the patients according to joint scores. The secondary aim was to obtain a systematic overview of the doses of coagulation factors prescribed for prophylaxis at the Malmo haemophilia treatment centre during a 6-year period. A retrospective survey of medical records for the years 1997-2002 and ...

    Also Ranks for: Prophylactic Treatment |  coagulation factor |  joint status |  trough levels |  bleeding frequency
    KOL Index score: 10484

    In order to describe the haemostatic role of a variation in inhibitor reactivity with different factor VIII (FVIII) concentrates, we have compared inhibitor titres against a panel of FVIII concentrates and correlated titre with the capacity to inhibit thrombin generation. Three plasma-derived concentrates were tested in vitro in mixing experiments with inhibitor plasmas from 11 patients with severe haemophilia A: Fanhdi, which contains von Willebrand factor (VWF) with a final ratio of ...

    Also Ranks for: Thrombin Generation |  factor viii |  kogenate bayer |  inhibitor titres |  vwf ratio
    KOL Index score: 9947

    Thrombin generation is a key process that determines the extent of a hemostatic plug or a thrombotic process. The ensuing thrombin burst is crucial for the formation of a stable fibrin clot. During its active life, thrombin exerts a multitude of highly regulated actions on the blood and the vessel wall, including the clotting of fibrinogen. The inappropriate generation of thrombin may lead to pathologic processes, foremost of which are hemorrhagic or thrombotic diseases. The coagulation ...

    Also Ranks for: Thrombin Generation |  blood development |  clot formation |  vitro tests |  thrombotic process
    KOL Index score: 9691

    The frequency of joint bleeds and orthopaedic joint scores were evaluated in 121 patients with severe haemophilia who had started prophylactic treatment with clotting factor concentrates at least once weekly before the age of 10. 75 of the patients started before the age of 3, 31 at the age of 3-5 and 15 at the age of 6-9. Each subgroup was evaluated separately. In addition, a regimen of one infusion weekly was compared with that of two (haemophilia B) or three (haemophilia A) infusions ...

    Also Ranks for: Severe Haemophilia |  primary prophylaxis |  early age |  joint bleeds |  prophylactic treatment
    KOL Index score: 9685

    The development of inhibitory antibodies to factor VIII is a serious complication of hemophilia. FEIBA (factor VIII inhibitor-bypassing activity), an activated prothrombin complex concentrate (aPCC), and NovoSeven, recombinant factor VIIa (rFVIIa), are used as hemostatic bypassing agents in treating patients with inhibitors. The FENOC study was designed to test equivalence of the products in the treatment of ankle, knee, and elbow joint bleeding. A prospective, open-label, randomized, ...

    Also Ranks for: Feiba Novoseven |  randomized comparison |  bypassing agents |  viia hemophilia |  efficacy products
    KOL Index score: 9542

    We report on a series of 108 elective orthopaedic surgical procedures. It includes 88 radiosynoviortheses and 20 major orthopaedic procedures, performed on 51 patients at nine centres worldwide. The average age of patients was 28.5 years (range 5-40 years), and the average follow-up time was 2 years (range 1-5 years). There were 82 good results, 15 fair and 11 poor. In the synoviorthesis group (41 patients, 88 synoviortheses) the average age was 14.3 years (range 5-40 years) and the ...

    Also Ranks for: Elective Orthopaedic Surgery |  inhibitor patients |  average age |  hemophilia hemostasis |  procedures factor
    KOL Index score: 9537

    It has been previously shown that patients with severe haemophilia and not receiving any prophylactic treatment render a high risk of reduced bone mineral density. The purpose of this study was to evaluate bone mineral density (BMD) in patients with haemophilia of different severity types and treatment. The study group consisted of 26 patients with severe haemophilia (aged 33.6 +/- 2.1) and 16 patients with mild haemophilia (aged 40.2 +/- 3.3). The BMD (g cm(-2)) was measured by ...

    Also Ranks for: Severe Haemophilia |  physical activity |  bmd patients |  bone mineral |  femoral neck
    KOL Index score: 9487

    OBJECTIVE: In order to correct the primary von Willebrand factor (VWF) defect and avoid supra-physiologic plasma levels of factor VIII, a pure VWF concentrate almost devoid of FVIII was developed and used in France since 1989.

    METHODS: The pharmacokinetic (PK) profile of the most recent version of this concentrate (Wilfactin; LFB, Les Ulis, France), treated with three virus-inactivation/removal methods (solvent/detergent, 35 nm filtration, dry heat treatment), was investigated in 25 ...

    Also Ranks for: Willebrand Factor |  vwf fviii |  pharmacokinetic studies |  viii content |  virus inactivation
    KOL Index score: 9406

    The by-passing agents, recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrate (APCC), are important tools in the treatment of patients with haemophilia A and high-responding inhibitory antibodies. It has been observed clinically that in some patients undergoing immune tolerance induction the bleeding frequency decreases, hypothetically caused by a transient haemostatic effect of infused FVIII not measurable ex vivo. We evaluated how by-passing agents and ...

    Also Ranks for: Apcc Fviii |  patients haemophilia |  factor viii |  thrombin generation |  titre inhibitors


    Erik Berntorp: Influence Statistics

    Sample of concepts for which Erik Berntorp is among the top experts in the world.
    Concept World rank
    sports questionnaires age #1
    individuals mild haemophilia #1
    septicaemia thrombosis #1
    tgacat pwh #1
    hemophilia patients studies #1
    combined sequential therapy #1
    hemophilia immunoglobulin injections #1
    fprp ftprp #1
    haemophilia mibs #1
    myocardial ischemia pwh #1
    surgeon hematologist #1
    diabetes hemophilia hepatitis #1
    inhibitor genetics #1
    respondents severe haemophilia #1
    2β34 #1
    adherence prophylactic #1
    girls oestrogen treatment #1
    inhibitor titres capacity #1
    normal level pwh #1
    factor multidose pharmacokinetics #1
    arthropathy p00002 #1
    surgery willebrand disease #1
    haemophilia ultrasound #1
    antibodies factor hemophilia #1
    primary bleeding indication #1
    fviii pwh #1
    inhibitors adherence #1
    hiv‐disease progression #1
    haemophilia meeting #1
    prophylactic treatment respondents #1
    higher hjhs patients #1
    joint bleeds adherence #1
    vwf adult blood #1
    vwd role #1
    factor desmopressin #1
    mhb mha #1
    professor björkman #1
    centers normalization #1
    thrombin generation tests #1
    relationship fviii #1
    global haemostatic inr #1
    fenoc #1
    impact inhibitor epitope #1
    hjhs moderate haemophilia #1
    renal insufficiency pwh #1
    effective health patients #1
    arcane guideline #1
    highly regulated actions #1
    aptt icu #1
    headus hjhs #1

    Key People For Factor Viii

    Top KOLs in the world
    Leon W Hoyer
    factor viii endothelial cells murine hemophilia
    Edward G D Tuddenham
    factor viii gene therapy monoclonal antibodies
    Pier Mannuccio Mannuccio Mannucci
    willebrand factor venous thromboembolism myocardial infarction
    Randal J Kaufman
    factor viii endoplasmic reticulum unfolded protein response
    Gordon A Vehar
    factor viii cytoplasmic domain plasminogen activator
    Pete Lollar
    factor viii immune response major determinant

    Erik Berntorp:Expert Impact

    Concepts for whichErik Berntorphas direct influence:Factor viii,  Severe haemophilia,  Willebrand disease,  Thrombin generation,  Severe hemophilia,  Willebrand factor,  Prophylactic treatment,  Hemophilia humans.

    Erik Berntorp:KOL impact

    Concepts related to the work of other authors for whichfor which Erik Berntorp has influence:Factor viii,  Willebrand disease,  Severe haemophilia,  Tranexamic acid,  Inhibitor development,  Thrombin generation,  Hemophilia humans.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    Department of Translational Medicine, Lund University, Malmö, Sweden | Clinical Coagulation Research, Department of Translational Medicine, Lund University, Malmö, Sweden | Skane University Hospital, Malmö, Sweden | Department of Translational Medici